This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PRX-3140

Nanotherapeutics, Inc.

Drug Names(s): PRX-03140, NTC-942

Description: PRX-03140 is a highly selective serotonin 4 (5-HT4) receptor partial agonist. Preclinical studies have shown that it improves cognitive function, as well as increases levels of acetylcholine (ACh), soluble amyloid precursor protein (sAPP) and brain-derived neurotrophic factor (BDNF) in regions of the brain known to be important for memory.

Deal Structure: In December 2006, GlaxoSmithKline (GSK) and EPIX Pharmaceuticals entered a multi-target strategic collaboration to discover, develop and market novel medicines targeting four G-protein coupled receptors (GPCRs) for the treatment of a variety of diseases, including PRX-03140, in early-stage clinical development for the treatment of Alzheimers disease. EPIX will be eligible to earn potential milestones of up to $1.2 billion based on the achievement of certain discovery, development, regulatory and commercial milestones across the four GPCR programs. EPIX will also receive tiered double-digit royalties on sales by GSK of all collaboration-developed product sales.

EPIX will be responsible for the discovery and development of small molecule drug candidates targeting four GPCRs, including PRX-03140 for the treatment of Alzheimers disease, through to clinical proof of concept, at which point GSK will have an exclusive option to license each product for further development and...See full deal structure in Biomedtracker

Partners: GlaxoSmithKline plc


PRX-3140 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug